Hubacek Jaroslav, Kalla Sunil, Galbraith P Diane, Graham Michelle M, Knudtson Merril L, Ghali William A
Department of Medicine, University of Calgary, Calgary, Canada.
Can J Cardiol. 2008 Feb;24(2):121-6. doi: 10.1016/s0828-282x(08)70567-1.
The best therapeutic strategy for patients with double-vessel coronary artery disease and proximal left anterior descending artery involvement (2VD + pLAD) is not clear.
To compare the survival experience of a cohort of cardiac catheterization patients with 2VD + pLAD based on chosen therapeutic strategy (medical management versus percutaneous coronary intervention [PCI] versus coronary artery bypass graft surgery [CABG]).
The authors identified and studied a total of 603 patients with 2VD + pLAD from all patients who underwent diagnostic coronary angiography in Alberta between January 1997 and May 1999. The primary end point was five-year survival from index catheterization for each of the treatment groups and from time of revascularization when the two revascularization strategies were compared.
Risk-adjusted hazard ratios (HR) comparing cumulative five-year survival rates of patients treated medically, or with PCI or CABG indicated a survival benefit for patients treated with CABG (HR 0.24, 95% CI 0.11 to 0.54; P<0.001) and PCI (HR 0.43, 95% CI 0.24 to 0.77; P=0.003) compared with medical management. Meanwhile, a risk-adjusted comparison of revascularization strategies suggested a possible trend toward higher mortality for PCI-treated patients versus CABG-treated patients (HR 1.56, 95% CI 0.65 to 3.72; P=0.125).
The results of this registry-based observational study suggest a survival benefit from revascularization compared with medical management in patients with 2VD + pLAD. Furthermore, the authors found a trend toward better survival in CABG-treated patients compared with PCI-treated patients.
双支冠状动脉疾病且累及左前降支近端(2VD + pLAD)患者的最佳治疗策略尚不清楚。
比较一组接受心脏导管插入术的2VD + pLAD患者基于所选治疗策略(药物治疗与经皮冠状动脉介入治疗[PCI]与冠状动脉旁路移植术[CABG])的生存经验。
作者从1997年1月至1999年5月在艾伯塔省接受诊断性冠状动脉造影的所有患者中识别并研究了总共603例2VD + pLAD患者。主要终点是每个治疗组自首次导管插入术起的五年生存率,以及在比较两种血运重建策略时自血运重建时间起的五年生存率。
比较接受药物治疗、PCI或CABG治疗患者的累积五年生存率的风险调整后危险比(HR)表明,与药物治疗相比,接受CABG治疗的患者(HR 0.24,95%CI 0.11至0.54;P<0.001)和PCI治疗的患者(HR 0.43,95%CI 0.24至0.77;P = 0.003)有生存获益。同时,血运重建策略的风险调整后比较表明,PCI治疗患者与CABG治疗患者相比可能有更高死亡率的趋势(HR 1.56,95%CI 0.65至3.72;P = 0.125)。
这项基于注册研究的观察性研究结果表明,与药物治疗相比,2VD + pLAD患者血运重建有生存获益。此外,作者发现CABG治疗患者与PCI治疗患者相比有更好生存的趋势。